| Methods |
RCT.
Open label.
Active controlled. |
| Participants |
153 participants with newly diagnosed OAG.
Racial constitution is not reported.
Inclusion criteria: IOP of 22 mmHg, visual field changes and/or disc changes suggestive of a diagnosis of POAG.
Exclusion criteria: IOP over 32 mmHg together with marked reduction of visual field, history of ocular trauma or surgery. |
| Interventions |
Timolol 0.25% twice daily.
Betaxolol 0.5% twice daily.
Carteolol 1% twice daily. |
| Outcomes |
Change of visual field mean deviation.
Incidence of visual field deterioration. |
| Notes |
Median follow up: timolol group 42 months, betaxolol group 24 months, carteolol group 36 months.
29 drop‐outs: 12 timolol group (7 local and 3 systemic side effects), 17 betaxolol group (5 systemic side effects), 19 carteolol (6 systemic side effects). |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
